Follow us on Twitter
twitter icon@FreshPatents


Vascular Diseases patents

      

This page is updated frequently with new Vascular Diseases-related patent applications.




 Heterocyclyl-butanamide derivatives patent thumbnailHeterocyclyl-butanamide derivatives
In which w, x and y have the meanings indicated in claim 1, are inhibitors of tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.. .

 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds patent thumbnailBeta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
Aerie Pharmaceuticals, Inc.


 Bioengineered allogeneic valve patent thumbnailBioengineered allogeneic valve
The present disclosure relates to methods for recellularization of valves in valve-bearing veins. This method is useful for producing an allogeneic venous valve, wherein a donor valve-bearing vein is decellularized and then recelluiarized using whole blood or bone marrow stem cells.
Novahep Ab


 Aplnr modulators and uses thereof patent thumbnailAplnr modulators and uses thereof
The present invention provides apelin receptor (aplnr) modulators that bind to aplnr and methods of using the same. The invention includes aplnr modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate aplnr-mediated signaling.
Regeneron Pharmaceuticals, Inc.


 Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases patent thumbnailEnantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases
The present application relates to novel 6-hydrogen-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. .
Bayer Pharma Aktiengesellschaft


 Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases patent thumbnailImidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases
The present application relates to novel heterocyclyl- and heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.. .
Bayer Pharma Aktiengesellschaft


 Imidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases patent thumbnailImidazo[1,2-a]pyridines as soluble guanylate cyclase stimulators for the treatment of cardiovascular diseases
The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.. .
Bayer Pharma Aktiengesellschaft


 Process for the synthesis of dabigatran etexilate and its intermediates patent thumbnailProcess for the synthesis of dabigatran etexilate and its intermediates
The present invention describes an improved process for the preparation of dabigatran etexilate (formula-vii) or it's pharmaceutically acceptable salt for the treatment of thrombosis, cardiovascular diseases etc. And intermediates involved in the synthesis..
Biophore India Pharmaceuticals Pvt. Ltd.


 Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors patent thumbnailMeldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
The disclosed subject matter provides certain n-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or development of a disease or condition.
The Johns Hopkins University


 Bioengineered allogeneic blood vessel patent thumbnailBioengineered allogeneic blood vessel
The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells.
Novahep Ab


Mangifera indica as a sirtuin 1 activating agent

The invention relates to a mangifera (mango) indica preparation as sirtuin 1 activating agent for in vivo and in vitro applications. The preparation may be used to reduce the risk of developing obesity, type ii diabetes, elevated blood lipid levels, artheriosclerosis and cardiovascular diseases, as well as a cell and dna protector..
Vital Solutions Swiss Ag

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of formula (i) and the pharmaceutically acceptable salts thereof, which are inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention..
Merck Sharp & Dohme Corp.

Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide for the treatment of eye diseases

The present invention relates n-(4-tert-butyl-benzyl)-3-chloro-n-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benz-amide which is useful in the prevention, treatment, delaying progression and/or reduction of eye diseases, in particular wherein the eye diseases are intraocular neovascular diseases and its method of preventing, retarding and ameliorating eye diseases, in particular intraocular neovascular diseases.. .
Hoffmann-la Roche Inc.

Novel macrocyclic compounds

The present invention relates to novel macrocyclic compounds of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Dietary compositions for reducing blood glucose levels and for weight management

The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, hypertension and cardiovascular diseases..
Marmar Investment Sp. Z O.o.

Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group

The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Inhibition of hypoxia-inducible factor activity with carica papaya extracts

An extract of carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed is used as an inhibitor of hif to effectively block hypoxia-inducible factor (hif) function and methods of use thereof. More specifically it relates to the use of the carica papaya plant extract to eliminate unwanted cells by inhibiting hif in the prevention and treatment of hypoxia-related conditions and diseases such as inflammatory diseases, vascular diseases, cancer and infectious diseases.
Universiti Putra Malaysia

Methods for analyzing rare circulating cells

The disclosure provides methods for analyzing rare circulating cells (rccs) at cellular and molecular level following their detection in non-enriched blood samples, methods of this disclosure serve as diagnostic methods for several disease conditions, including cardiovascular diseases and cancer.. .
Epic Sciences, Inc.

Uses of diazepane derivatives

The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.

Imidazopyrazinone derivatives

In which r1 and r2 have the meanings indicated in claim 1, are inhibitors of tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.. .

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Triarylmethane analogs and their use in treating cancers

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs.
U.s. Government As Represented By The Department Of Veterans Affairs

Hormone treatment for age-related hearing loss-presbycusis

Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the us alone. There are currently no fda-approved drugs on the market in the us, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness.
University Of South Florida

Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Compositions and methods for delivering microrna

The invention relates to compositions, methods and kits for using argonaute-2 (ago-2) as a systemic carrier to deliver a mirna to an endothelial cell. The invention also relates to compositions, methods and kits for inhibiting angiogenesis and/or treating a condition by using ago-2 as a systemic carrier to deliver a mirna to an endothelial cell.
University Of Southern California

Inhibitors of c-jun-n-terminal kinase (jnk)

Where ring a, ring b, x, l1, l2, ra, rc, rd, re, m, n, and p are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of human diseases associated with kinase activity, for example, proliferative diseases, neurodegenerative diseases, metabolic disorders, inflammatory diseases, and cardiovascular diseases..

Ultrasound molecular imaging with targeted biocompatible microbubbles

The present invention is related to cardiovascular contrast agents. In particular, compositions and methods for ultrasound cardiovascular contrast agents useful for molecular imaging and/or diagnosis of cardiovascular diseases and disorders.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Use of chec peptides to treat neurological and cardiovascular diseases and disorders

The present invention describes compositions and methods for treating and preventing non-degenerative neurological diseases and disorders associated with elevated spla2 activity as well as cardiovascular diseases using a chec peptide to inhibit spla2 activity.. .
Drexel University

Saxatilin-fc fusion protein and use thereof

The present invention relates to a saxatilin derivative having an increased half life and a use thereof. The saxatilin derivative of the present invention has thrombolytic ability similar to that of saxatilin, which is the mother protein, a remarkably increased protein half life, and efficiently dissolves, for long period of time, blood clots already formed in blood vessels of an animal model with a fecl3-induced carotid by using the same.
Industry-academic Cooperation Foundation, Yonsei University

Dihydropteridinone derivatives and uses thereof

The present invention provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.

Diazepane derivatives and uses thereof

The present invention provides compounds of any one of formulae (i), (ii-c) (e.g., formula (ii)), and (iii), and pharmaceutically compositions thereof. Compounds of any one of formulae (i), (ii-c), and (iii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.

Apparatus and treating cardiovascular diseases

A removable apparatus is provided for temporary implantation in a pulmonary vein for ablating atrial tissue surrounding the antrum of the pulmonary vein to treat atrial fibrillation in a subject. The apparatus comprises an electrically-insulated expandable support member and a retrieval mechanism.
The Cleveland Clinic Foundation

Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases

The present invention relates to compositions and methods for treatment and/or prevention of a cardiovascular disease. In one embodiment, the invention provides compositions and methods for decreasing one or more of the level, production, and activity of ezh2..
University Of Rochester

Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders..
The Johns Hopkins University

Methods of treating or preventing vascular diseases of the retina

The present invention features, in part, methods of treating or preventing vascular diseases of the retina in a subject, methods of treating or preventing angiogenesis in a subject and methods of treating or preventing neovascularization in a subject comprising administering to a subject a therapeutically effective amount of an inhibitor of cytochrome p450 2c8 (cyp2c8) activity or expression, or a promoter of seh activity or expression.. .
Children's Medical Center Corporation

Pro-angiogenic peptides and peptide conjugates

Short bioactive sequences derived from the 2nd loop of the 7-transmembranal receptor of endothelial differentiation gene 3 (edg3) useful in stimulation of angiogenesis, and peptide conjugates comprising a permeability enhancing moiety, are provided. Also provided are pharmaceutical compositions comprising the peptides and methods of use in conditions were insufficient blood-supply occurs, or which are associated with endothelia dysfunction such as peripheral vascular diseases, coronary artery diseases, cerebrovascular diseases, diabetes and delayed wound healing, pulmonary disease, eye diseases and pathological condition related to severe infection..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Beta-hairpin peptidomimetics as selective elastase inhibitors

β-hairpin peptidomimetics of the general formula cyclo(-xaa1-xaa2-thr3-xaa4-ser5-xaa6-xaa7-xaa8-xaa9-xaa10-xaa11-xaa12-xaa13-) and pharmaceutically acceptable salts thereof, with xaa1, xaa2, xaa4, xaa6, xaa7, xaa8, xaa9, xaa10, xaa11, xaa12 and xaa13 being amino acid residues of certain types which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity.
Polyphor Ag

Diaminopyrimidine benzenesulfone derivatives and uses thereof

The present invention provides compounds of formula (ii) (e.g., compounds of formula (i)), and pharmaceutically compositions thereof. Compounds of formula (ii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.

Compositions and methods for treating cardiovascular diseases

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.. .
Infirst Healthcare Limited

Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase

The present invention relates to compounds of the formula (i), wherein r1, r2, r3, r4 and x have the meanings indicated in the claims. The compounds of formula i are valuable pharmacologically active compounds.
Sanofi

Compounds with neural protective effect, and preparation and use thereof

The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as alzheimer's disease, parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases..

Liver x receptor agonists and uses thereof

Disclosed herein are antibody drug conjugates having an antibody or antibody fragment that binds a cell surface molecule on a target cell, wherein the target cell is a lymphocyte and a therapeutic agent that has a therapeutic effect in a subject in need thereof. Further disclosed herein are antibody drug conjugates having an antibody or antibody fragment that binds a cell surface molecule on a target cell; and a therapeutic agent that binds an intracellular moiety of the target cell.
The California Institute For Biomedical Research

Inhibitors of the renal outer medullary potassium channel

Novel spirocyclic compounds of formula i: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the romk (kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Merck Sharp & Dohme Corp.

Beta-hairpin peptidomimetics as selective elastase inhibitors

β-hairpin peptidomimetics of the general formula cyclo(-xaa1-xaa2-thr3-xaa4-ser5-xaa6-xaa7-xaa8-xaa9-xaa10-xaa11-xaa12-xaa13-) and pharmaceutically acceptable salts thereof, with xaa1, xaa2, xaa4, xaa6, xaa7, xaa8, xaa9, xaa10, xaa11, xaa12 and xaa13 being amino acid residues which are defined in the description and the claims, have elastase inhibitory properties, especially against human neutrophil elastase, and can be used for preventing infections or diseases related to such infections in healthy individuals or for slowing infections in infected patients. The compounds of the invention can further be used where cancer, or immunological diseases, or pulmonary diseases, or cardiovascular diseases, or neurodegenerative diseases, or inflammation, or diseases related to inflammation, are mediated or resulting from elastase activity.
Polyphor Ag

Apoptosis signal-regulating kinase inhibitors

The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ask1), thus are thus useful in treating ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.. .
Gilead Sciences, Inc.

Tonabersat prodrugs

The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced) or cardiovascular diseases including myocardial infarction, coronary revascularization or angina. The compounds of the invention form a novel group of related prodrugs of formula (ii), where ar is a 3-chloro-4-fluorophenyl ring, a 3-chlorophenyl ring or a 4-fluorophenyl ring; and r is a hydrolysable group comprising an amino group or an acidic group..
Proximagen Limited

Phthalazine derivatives

In which r1, x and n have the meanings indicated in claim 1, are inhibitors of tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.. .

Perivascular mesenchymal precursor cell induced blood vessel formation

Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3g5, and preferably also alpha smooth muscle actin together with early developmental markers such as stro-1 and cd146/muc18.
Mesoblast, Inc.



Vascular Diseases topics:
  • Vascular Disease
  • Vascular Diseases
  • Cardiovascular
  • Cardiovascular Disease
  • Inflammatory Disease
  • Antimicrobial
  • Antimicrobial Agents
  • Antimicrobial Agent
  • Pharmaceutically Acceptable Salt
  • Inflammation
  • Atherosclerosis
  • Pharmaceutically Acceptable Salts
  • Oestrogens
  • Hyperlipidemia
  • Steoporosis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Vascular Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vascular Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2627

    file did exist - file did put2733

    3 - 1 - 51